Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5
12-Mar-2007 -
Liponex Inc. announced results of the Phase I/II Clinical Trial of its lead product, CRD5. CRD5 is being developed for the treatment of dyslipidemia and heart disease. Results showed, to date, that CRD5 was safe and that the drug formulation was stable throughout the trial. However, the mean ...
cardiovascular diseases
clinical trials
density